Lecanemab (Mouse IGG2a) (Mab158) is a monoclonal antibody that targets soluble beta-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) almost abolishes Abeta accumulation in astrocytes and rescues neurons from Abeta-induced cell death. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimers disease[1][2][3].
Molecular Weight:
(147.71 kDa)
Purity:
99.88
Target:
Amyloid-beta
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
